<img alt="" src="https://secure.intelligent-consortium.com/791519.png" style="display:none;">

Psomagen Offers Long-Read Sequencing with the PacBio Sequel IIe

Psomagen Blog

Psomagen Offers Long-Read Sequencing with the PacBio Sequel IIe


ROCKVILLE, Md. — October 2022 — Psomagen, Inc. has announced they are now able to provide PacBio sequencing services to North American customers. This partnership, offered through their South Korean parent company, Macrogen, gives sequencing clients access to the PacBio Sequel IIe. 

The Sequel Ile gives HiFi sequencing capabilities to researchers, with immediate insight into the epigenome by detecting 5mC bases at CpG sites. This technology offers accurate long-read sequencing data and information on areas of methylation across the whole genome. 

“This is an exciting opportunity for Psomagen,” says Dr. Su Hong, CEO of Psomagen. “PacBio is leading the way with high-capability long-read sequencing technologies. This certification gives Psomagen and Macrogen customers the confidence to sequence with us for major biological insights and meaningful data analysis.” 

Macrogen has been a PacBio Certified Service Provider since 2015, when they completed their certification. This program ensures that Macrogen employees have the most up-to-date training on PacBio workflows. Macrogen is a longstanding provider of the PacBio RS II, their first iteration of sequencing technology. 

“We are thrilled to proceed with this next step in the relationship between our companies and PacBio,” says Dr. Hong. “Our goal is always to provide the best in multiomics capabilities to our clients; this addition to our available technologies is a new, versatile option to obtain genomic and epigenomic insights from a single sample.”  

The Sequel IIe adds to Psomagen's existing long-read and short-read sequencing platforms. These options enable Psomagen customers to conduct whole-genome and whole-exome sequencing, as well as transcriptomic, proteomic, and metagenomic projects. 

About Psomagen, Inc.
Psomagen, Inc., formerly Macrogen Corp, is a North American integrative omics solutions and contract laboratory services provider. The company makes cutting-edge technology and data analysis accessible to the clinical and academic markets. With both CLIA-certified and CAP-accredited facilities, their team delivers only the highest-quality integrative multi-omics data using best-in-class DNA, RNA, and protein analysis systems. In conjunction with its bioinformatics capabilities, Psomagen offers a path to insights that is both simple and affordable. Learn more at psomagen.com.


Abhilasha Cheruku
Product Manager
Psomagen, Inc. 


About Macrogen
Macrogen was founded in 1997 in Seoul, South Korea. In 2000, they became the first Korean bio venture to be listed on the KOSDAQ. Since then, Macrogen has expanded their reach in the genomics and genetics R&D fields. Today, the company has locations across Europe, as well as offices in Singapore, Tokyo, and Chile. Their subsidiary, Psomagen, offers multiomics services to North American customers. Macrogen continues to offer genomic analysis services to clients in over 150 countries. Learn more at macrogen.com.


About Pacific Biosciences
PacBio is a California-based provider of sequencing solutions that solve complex genomics problems. Their sequencers are designed to create more complete images of the genome, transcriptome, and epigenome. PacBio users have made contributions to rare disease research, public health surveillance, pharmaceutical development, and many other fields. Learn more at pacb.com.